Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.7K
1.7K
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

1.9K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.9K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

63
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
63
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

6.3K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Machine Learning Assessment of Pathologic Response in Lung Cancer Resections After Neoadjuvant Therapy-IASLC MPR Project.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026
Same author

Sasanlimab taken together with Bacillus Calmette-Guérin (BCG) compared with BCG alone in people with high-risk non-muscle invasive bladder cancer: a plain language summary.

Future oncology (London, England)·2026
Same author

Sex differences in nerve injury-induced neuropathic pain via REST in primary sensory neurons.

Neurobiology of pain (Cambridge, Mass.)·2026
Same author

Long-Term Outcomes After Proton Therapy Versus Intensity Modulated Photon Radiation Therapy With Concurrent Chemotherapy for Locally Advanced Non-Small Cell Lung Cancer: Post Hoc Analysis of a Prospective Randomized Trial.

International journal of radiation oncology, biology, physics·2026
Same author

Proton versus photon therapy for oropharyngeal cancer - Authors' reply.

Lancet (London, England)·2026
Same author

MDASI-HN Symptom Profiling for Early-Risk Stratification of Hypoglossal Neuropathy in Survivors of Oropharyngeal Cancer.

JAMA otolaryngology-- head & neck surgery·2026
Same journal

Design of Trials with Composite Endpoints with the R Package CompAREdesign.

Statistics in biosciences·2026
Same journal

Pan-Cancer Drug Response Prediction Using Integrative Principal Component Regression.

Statistics in biosciences·2026
Same journal

Variance Estimation for Weighted Average Treatment Effects.

Statistics in biosciences·2026
Same journal

Bayesian Modeling on Microbiome Data Analysis: Application to Subgingival Microbiome Study.

Statistics in biosciences·2026
Same journal

Canopy2: Tumor Phylogeny Inference by Bulk DNA and Single-Cell RNA Sequencing.

Statistics in biosciences·2026
Same journal

Multilevel Multivariate Functional Principal Component Analysis of Evoked and Induced Event-Related Spectral Perturbations.

Statistics in biosciences·2026
See all related articles

Related Experiment Video

Updated: Mar 15, 2026

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

8.1K

Bayesian Two-stage Biomarker-based Adaptive Design for Targeted Therapy Development.

Xuemin Gu1, Nan Chen1, Caimiao Wei1

  • 1Department of Biostatistics, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA.

Statistics in Biosciences
|September 13, 2016
PubMed
Summary
This summary is machine-generated.

This study introduces a Bayesian adaptive randomization design to improve targeted cancer drug development. It efficiently tests efficacy, identifies biomarkers, and personalizes patient treatment in real-time.

Keywords:
Adaptive DesignBayesian LassoOutcome-Adaptive RandomizationPersonalized MedicinePredictive and Prognostic BiomarkersTargeted TherapyVariable Selection

More Related Videos

Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization
03:08

Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization

Published on: October 3, 2025

1.1K
Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
07:40

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis

Published on: March 20, 2021

18.7K

Related Experiment Videos

Last Updated: Mar 15, 2026

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

8.1K
Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization
03:08

Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization

Published on: October 3, 2025

1.1K
Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
07:40

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis

Published on: March 20, 2021

18.7K

Area of Science:

  • Biostatistics
  • Clinical Trial Design
  • Personalized Medicine

Background:

  • Developing targeted agents requires efficient clinical trial designs.
  • Identifying predictive biomarkers is crucial for personalized medicine.
  • Adaptive randomization offers flexibility in trial conduct.

Purpose of the Study:

  • To propose a Bayesian two-stage biomarker-based adaptive randomization (AR) design.
  • To test treatment efficacy and identify prognostic/predictive markers.
  • To enhance patient treatment through real-time adaptive strategies.

Main Methods:

  • A two-stage Bayesian adaptive randomization design incorporating biomarker profiles.
  • Stage 1: Known marker-based AR with Go/No-Go decision.
  • Stage 2: Bayesian lasso for biomarker selection to refine AR.

Main Results:

  • Simulations demonstrate excellent operating characteristics.
  • Effective control of Type I and Type II errors.
  • High probability of selecting important biomarkers and improved patient treatment.

Conclusions:

  • Bayesian adaptive designs facilitate continuous learning in clinical trials.
  • The proposed design is suitable for developing multiple targeted agents.
  • Real-time data utilization guides treatment selection for personalized outcomes.